Back to news

Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results

Globe Newswire•16/11/2026•16:01 ET
0

Key Highlights

  • ➤Q3 revenue $10.4 million, up 18% year-over-year
  • ➤Q3 Adjusted EBITDA $2.1 million, margin expanded to 20%
  • ➤Q3 thyroid test volume increased 7% year-over-year
  • ➤Q3 thyroid revenue increased 18% year-over-year
  • ➤Trailing twelve-month thyroid revenue reached $38.0 million, up 13%

Expert Statements

Chris McCarthy, Chief Financial Officer of Interpace Biosciences

“The Company continued to convert revenue growth into margin expansion in the third quarter, reflecting the operating leverage we have built into the business”

Chris McCarthy, Chief Financial Officer of Interpace Biosciences

“Gross margin expanded to 69% in Q3 2026, up from 62% in Q3 2025 and 63% on a Pro Forma basis, supported by an 11% increase in average thyroid revenue per test and continued efficiency gains in our laboratory.”

Chris McCarthy, Chief Financial Officer of Interpace Biosciences

“That gross margin expansion carried through to the bottom line: Adjusted EBITDA margin improved to 20% from 14% in the prior year quarter and 17% on a Pro Forma basis, with Adjusted EBITDA increasing to $2.1 million from $1.3 million.”

Chris McCarthy, Chief Financial Officer of Interpace Biosciences

“Q3 2026 revenue grew 18% to $10.4 million, or 15% on a Pro Forma basis, on 7% growth in thyroid test volume.”

Chris McCarthy, Chief Financial Officer of Interpace Biosciences

“Our debt-free balance sheet continues to support meaningful investment in laboratory automation, AI-enabled productivity initiatives across our workflow, and research and development to advance our pipeline.”

Chris McCarthy, Chief Financial Officer of Interpace Biosciences

“We are scaling operating leverage in line with volume growth without a corresponding increase in headcount, which we expect will support continued margin expansion.”

Tom Burnell, President and CEO of Interpace Biosciences

“The third quarter demonstrates the durability of the business we built through last year’s transition and the operating discipline we will carry through the remainder of 2026 and into 2027.”

Tom Burnell, President and CEO of Interpace Biosciences

“We see the same characteristics in Q3 2026 that defined our 2025 performance — disciplined execution, expanding clinical adoption, and a steady cadence of operational improvement.”

Tom Burnell, President and CEO of Interpace Biosciences

“We continue to believe our combination approach — ThyGeNEXT(®) for mutation detection and ThyraMIR(®)v2 for microRNA pathway insights — gives physicians the confidence and clarity they need to make informed patient-management decisions.”

* Q3 Revenue of $10.4 million * Q3 Thyroid volume year-over-year increase of 7% * Q3 Thyroid revenue year-over-year increase of 18% * Trailing twelve-month thyroid revenue of $38.0 million, an increase of 13% on a comparable thyroid-only basis PARSIPPANY, NJ, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCID: IDXG) today announced financial results for the third quarter ended September 30, 2026 and provided a business and financial update.

Interpace generated Q3 2026 revenue of $10.4 million, up 18% year-over-year, a loss from continuing operations of $1.5 million compared to income from continuing operations of $1.0 million in the prior year, and produced Adjusted EBITDA of $2.1 million, or 20% of revenue. The loss from continuing operations of $1.5 million included approximately $4.1 million of non-recurring stock compensation costs and non-recurring legal expenses.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in